← FDA DRUG APPROVALS

FDA ANDA · ANDA077037

CITALOPRAM HYDROBROMIDE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA077037
TYPE
ANDA
ORIGINAL APPROVAL
2004-11-05
LATEST ACTION
2024-11-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL

Approval history

2024-11-25Labeling · Supplement 9 · standardAP
2024-06-17Labeling · Supplement 8 · standardAP
2024-06-17Labeling · Supplement 7 · standardAP
2009-03-30Labeling · Supplement 5AP
2008-09-24Labeling · Supplement 4AP
2007-10-22Labeling · Supplement 3AP
2006-02-14Labeling · Supplement 2AP
2005-08-01Labeling · Supplement 1AP
2004-11-05Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →